MedTrace Logo

Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

NCT01015339 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2015-05-19

No results posted yet for this study

Summary

The purpose of this study is to investigate whether Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment as 1st line treatment in he advanced gastric cancer is effective and safe.

Conditions

  • Advanced Gastric Cancer

Interventions

DRUG

Paclitaxel

80mg/m2 infusion,d1,d8 every 3 weeks

DRUG

capecitabine

Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks

DRUG

capecitabine

Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks

DRUG

cisplatin

80mg/m2, day 1 of every 3 weeks

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Peking University

    lead OTHER

Principal Investigators

  • Lin Shen, MD · Peking University, School of oncology, Department of GI oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01015339 on ClinicalTrials.gov